Bivin & Associates’s Precision BioSciences DTIL Stock Holding History

Bivin & Associates’s Portfolio DTIL Stock Details DTIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-3	Closed	-$1K	–	369
2021 Q4	$1K	Buy	+3	New	+$838	﹤0.01%	296

Other funds holding DTIL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

OMC

OUP Management Company Bala Cynwyd, Pennsylvania $44.5M AUM 55.11% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Bivin & Associates's DTIL Position: Q1 2022 in Review

Bivin & Associates sold out of Precision BioSciences (DTIL) in Q1 2022, closing a stake of 3 shares — an estimated $1K sold.

Bivin & Associates first reported a position in DTIL in Q4 2021 and held it in 1 quarter. The position peaked at $1K in Q4 2021. 152 funds tracked by Wall St. Rank hold DTIL as of Q1 2022.

Bivin & Associates reported no remaining Precision BioSciences position as of Q1 2022 after selling out during the quarter.
Bivin & Associates sold 3 Precision BioSciences shares in Q1 2022, an estimated $1K.
Bivin & Associates first reported a position in Precision BioSciences in Q4 2021 and held it in 1 quarter.
Bivin & Associates's Precision BioSciences position peaked at $1K in Q4 2021.
152 funds tracked by Wall St. Rank held Precision BioSciences as of Q1 2022.

Based on Bivin & Associates's 13F filing for Q1 2022, filed 6 May 2022.